Bristol-Myers Squibb

Options? Are You Nuts?! Wed, 12/22/2010 - 09:46 by John Rosevear So how about that stock market rally? You think the recent dip was a speed bump? Or are we looking at another big drop sometime soon? Comments Read more	How Cheap Is Bristol-Myers Squibb's Stock by the Numbers? Sun, 12/19/2010 - 09:29 by Anand Chokkavelu Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues: Comments Read more	Black Friday Biotech Bargains Sat, 11/27/2010 - 10:17 by Brian Orelli It's Black Friday -- time to go shopping for biotech bargains, drugmakers that have been kicked to the curb but have the potential to get back up for another fight. Comments Read more
Where Is Bristol-Myers Squibb's Bottom Line Headed? Thu, 10/21/2010 - 10:26 by Seth Jayson Margins matter. The more Bristol-Myers Squibb (NYSE: BMY) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Bristol-Myers Squibb's competitive position could be. Comments Read more	Bristol-Myers Squibb Wed, 10/13/2010 - 12:28 by Brian Orelli After Bristol-Myers Squibb (NYSE: BMY) and Exelixis (Nasdaq: EXEL) split up on XL184 last June, you'd think one side would be a little bitter. Comments Read more	Pipeline Review: Bristol-Myers Squibb's 5 Keys to Success Wed, 09/01/2010 - 23:07 by Brian Orelli Bristol-Myers Squibb (NYSE: BMY) is facing the loss of its most important drug, Plavix, but still plans to keep earnings per share above 2009 levels after the drug begins facing generic competition in 2012. Comments Read more
Marginal Performance at Celgene Sat, 08/14/2010 - 12:28 by Seth Jayson Margins matter. The more Celgene (Nasdaq: CELG) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Celgene's competitive position could be. Comments Read more	Bristol-Myers Squibb: Warming Up or Cooling Off? Fri, 07/23/2010 - 23:58 by Motley Fool Together, we are all trying to build our fortunes by finding well-run companies at bargain-basement prices. But it takes work to scour earnings reports, scrutinize key data, and assess the competition. Comments Read more	Bristol-Myers Squibb announces approval of ORENCIA Wed, 07/07/2010 - 17:26 by Anupreet Kaur Bristol-Myers Squibb Company (NYSE: BMY), a global biopharmaceutical company, announced the approval of ORENCIA (abatacept), in combination with methotrexate (MTX), from the European Commission. The medicine is particularly for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients, who have responded inadequately to previous therapy, with one or more disease-modifying anti-rheumatic drugs (DMARDs) including MTX or a TNF-alpha inhibitor. “This is a very welcome decision from the European Commission and one which will potentially have a positive impact on treatment outcomes for RA patients who have already experienced inadequate response to a first DMARD,” said Dr. Manuela Le Bars, European Medical Lead for Immunoscience, Bristol-Myers Squibb. Comments Read more
Melanoma drug from Bristol shows promise Sun, 06/06/2010 - 12:31 by Jamie Anderson In what may be considered as a major breakthrough, U.S. researchers have found that Bristol-Myers Squibb Co.'s (BMY.N) skin cancer drug added, on average, four months to the lives of patients suffering from Melanoma, a lethal form of skin cancer. Comments Read more	US stocks rise after approval of health bill Tue, 03/23/2010 - 14:59 by Ishita Sood U.S. stocks rose on Monday after the health care overhaul bill was approved by the Senate on Sunday evening. Comments Read more	Up 80%, It's Time to Sell Wed, 11/18/2009 - 14:14 by Brian Orelli After seeing shares of its spinoff Mead Johnson Nutrition (NYSE: MJN) nearly double since its IPO in February, Bristol-Myers Squibb (NYSE: BMY) has decided now's the time to sell the 83% of the baby formula producer that it still owns. Comments Read more